TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Milk DHA+EPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insurance coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Access to primary care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPEP occurrence
Endpoint domain: Mortality/survival
Primary endpoint: PMI occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac T2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of responses to a community-wide survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative probability of being hospitalised with pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Serum retinol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postoperative function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Virologic Suppression (VS) at <200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Suppression (VS) at <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-VAS response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global-VAS response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of graft coronary vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of ACTH and cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count leukocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bleeding sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intraocular pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of medications required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Requirements for additional glaucoma surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hematoma formation
Endpoint domain: Adverse events/effects
Primary endpoint: onset of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: number of misoprostol doses needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sealant retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries free occlusal surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of treated biopsy‐proven acute rejection, graft loss, death, or premature study discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: EQ-5D-3L utility score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QOLIE-31P scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk of SGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of CPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved overall physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced stress/anxiety and enhanced calmness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enriched quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of HRV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systemic mean blood pressure (mBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systemic vascular resistance (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vein graft flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental efficacy and safety of dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS during suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS at the end of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fat Mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting Energy Expenditure (REE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial intestinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrence of total side‐effects
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day MAE rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve functional milestones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reversion rates of MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total BMIPP uptake scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurocognitive test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Half-life of CO elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite rate of death, MI, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: all-cause mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: rates of death, MI, stroke, or repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: monthly new CEL rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complications associated with pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Blood flow velocity in the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ocular fundus pulsations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in vaccine status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of HPV vaccine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' contentment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volume of HES vs. NaCl to reach HDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach HDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Costs related to recurring UCB
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the serum drug concentration‐time curve (AUC0‐t) of oxybutynin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration of oxybutynin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events after oxybutynin administration
Endpoint domain: Adverse events/effects
Primary endpoint: Minnesota Living with Heart Failure Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PTSD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance use treatment retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to cataract surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision loss of 2 lines or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: non-haematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: MITI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in malondialdehyde (MDA) generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of perceived exertion (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Histological AK clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of cleared lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Blood Pressure (SBP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Repeat revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial infarction (MI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Favorable functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MBVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: A x beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum EPO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum transferrin receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical complete remission rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-year local progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Overexpression of PPAR‐γ, AKT, PI3K, IRS1, and GLUT4 genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of PKC and LDLR genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavorable clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rumination activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBDQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual analogue pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar fascia thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centre of pressure velocity during loading response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGG maximums
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the concentration time curve (AUC) of etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve (AUC) of etoposide catechol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catechol to etoposide AUC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakthrough varicella incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Signal changes in contralateral testes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital transfers
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Glycated hemoglobin A1C (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose (BG) <180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Medication adherence (Modified Morisky Score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HAQ-DI scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DAS28-4(ESR) less than 2.6 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to obtain endocervical cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inquiries about physical abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total body fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: android fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gynoid fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bisphosphonate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate care received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Smoking relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anginal attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to clinically important decrease in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: plasma tryptophan concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-hydroxyindole acetic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perceptual threshold for first perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in LANSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in negative emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in positive emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative elbow extension deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QuickDash results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage reduction in total lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shear Bond Strength (SBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesive Remnant Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: stability of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slowing of progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: mean estimated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean fall in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean fall in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in AI75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of proteins and RNAs from urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of granulocyte-platelet aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduced CD62P expression on platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduced clot firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of MPE after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hypochondriasis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in somatization and depression-anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean pulmonary artery pressure (MPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NPRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone disintegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum C (max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PTH(min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appetite reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes